Bio-Path Holdings, Inc. (NASDAQ:BPTH) was up 6.5% on Monday . The stock traded as high as $0.43 and last traded at $0.41. Approximately 1,162,686 shares changed hands during mid-day trading, an increase of 188% from the average daily volume of 404,232 shares. The stock had previously closed at $0.39.
Several equities research analysts have recently weighed in on BPTH shares. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Bio-Path Holdings in a research report on Tuesday, July 4th. ValuEngine cut Bio-Path Holdings from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Finally, Zacks Investment Research cut Bio-Path Holdings from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th.
The firm’s market capitalization is $56.53 million. The firm’s 50 day moving average is $0.34 and its 200-day moving average is $0.45.
Bio-Path Holdings (NASDAQ:BPTH) last issued its earnings results on Thursday, August 10th. The company reported ($0.03) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.01). Equities analysts anticipate that Bio-Path Holdings, Inc. will post ($0.08) EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. HighTower Advisors LLC boosted its stake in shares of Bio-Path Holdings by 0.3% during the 2nd quarter. HighTower Advisors LLC now owns 1,267,070 shares of the company’s stock worth $492,000 after acquiring an additional 4,000 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Bio-Path Holdings by 1.7% during the 1st quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock worth $257,000 after acquiring an additional 5,172 shares during the period. Sabby Management LLC boosted its stake in shares of Bio-Path Holdings by 3.5% during the 1st quarter. Sabby Management LLC now owns 687,398 shares of the company’s stock worth $569,000 after acquiring an additional 23,352 shares during the period. Tower Research Capital LLC TRC bought a new position in shares of Bio-Path Holdings during the 1st quarter worth approximately $105,000. Finally, Legal & General Group Plc boosted its stake in shares of Bio-Path Holdings by 5,474.3% during the 2nd quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock worth $681,000 after acquiring an additional 1,741,978 shares during the period. Institutional investors own 15.16% of the company’s stock.
WARNING: “Bio-Path Holdings, Inc. (BPTH) Trading Up 6.5%” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://sportsperspectives.com/2017/10/11/bio-path-holdings-inc-bpth-trading-up-6-5.html.
Bio-Path Holdings Company Profile
Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.
Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.